Full-Time

Sr Manager

Patient Safety & Pharmacovigilance, Standards & Training

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

Compensation Overview

$133k - $209k/yr

+ Short-term Incentives + Long-term Incentives

Senior

Massachusetts, USA

The job is fully remote but is specifically targeting candidates based in the USA, particularly Massachusetts.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s degree in a scientific discipline or related field, preferably Health Care Professional
  • Minimum of 5 years prior experience in pharmaceutical industry in a drug safety/pharmacovigilance global setting
  • Experience in with training adult learners and developing procedural documents and training materials
  • Ability to work and collaborate in a global environment with cross-functional teams, with excellent interpersonal skills, assertiveness, and team spirit
  • Ability to manage both time and priority constraints with strong attention to detail in establishing priorities and meeting deadlines
  • Ability to lead teleconferences and meetings
  • Proactive, takes initiative, works independently, and manages multi-priority tasks
  • Excellent computer literacy, especially with Microsoft applications
Responsibilities
  • Ensures adequate training support to all functional areas within PSPV in a Pharmacovigilance (PV) regulated environment
  • Supports the development and delivery of PSPV employee training to ensure they possess the appropriate curriculum necessary for their role and function
  • Manages the Learning Management System (LMS) to ensure controlled development, delivery, and deployment of training
  • Monitors and tracks training compliance with the LMS
  • Provides Standards & Training subject matter insights within and outside of the PSPV function
  • Interfaces and collaborates with cross-functionally with other functions including but not limited to PSPV sub-functions, Documentation & Learning Excellence (DLE), PV Medica Quality (PVMQ)
  • Supports global PV Standards activities including procedure/process preparation, writing, content finalization, and maintenance, with support from subject matter experts, external functional areas, and QA
  • Supports new employee onboarding and training activities
  • Reviews and provides input into global PV SOPs and other relevant Takeda functional area Standard Operating Procedures (SOPs) to meet global PV requirements
  • Monitors, interprets, and communicate regulatory requirements and ensure global standards, SOPs, and all associated documentation is in line with global regulatory requirements and global PV SOPs
  • Contributes as the member to assigned projects and provide strategic insight at global level
  • Participate in and support for PV audit/Inspection and ensure its readiness with compliance and training team
  • Escalate issues / problems to line manager as needed

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines for patients. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized in all operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene could enhance its immunology and neurology offerings.
  • The SEA AtM Summit highlights Takeda's commitment to expanding access to medicines in Asia.
  • Positive Phase III trial results for a cancer drug strengthen Takeda's oncology portfolio.

What critics are saying

  • Antitrust litigation in the US could impact Takeda's market position and reputation.
  • The $770 million deal with BridGene poses financial risks if outcomes aren't met.
  • Geopolitical risks could disrupt Takeda's global operations and supply chain.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and innovations.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Nyasa Times
Feb 6th, 2025
Forgotten Children: Mzimba's Tukuyu CBCC Struggles to Provide Basic Education

VillageReach, in partnership with Takeda Pharmaceutical Company Limited, has launched a new initiative aimed at strengthening health systems and improving...